Pluton Biosciences, LLC
Formerly Pluton Biosciences, LLC
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2023 | $18 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2021 | $7 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pluton Biosciences, LLC reported revenue of $476,675 for its fiscal year to 31 December 2020 (filed Apr 2021), up from $19,431 the year before.
SEC Form C-AR · Apr 2021
The direct cost of what it sold was $188,857, so 60% of its revenue was left after those costs.
SEC Form C-AR · Apr 2021
Net loss for the same year: $979,712.
SEC Form C-AR · Apr 2021
Pluton Biosciences, LLC chose not to state its revenue in its newest notice of a funding round (Jun 2023).
SEC Form D · Jun 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2023
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of Pluton Biosciences, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 38 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Barry Goldman | Director; Founder; President; Chief Science Officer; Secretary | Jun 2023 |
| Elizabeth Gallegos | Director; Chief Executive Officer | Jun 2023 |
| Charles Walch | Executive officer | Oct 2021 |
| Steven Slater | Executive officer | Oct 2021 |
| Barry Goldman | Director; Founder; President; Chief Science Officer; Secretary | Jun 2023 |
| Charles Lin | Director | Jun 2023 |
| Clay Mitchell | Director | Jun 2023 |
| Elizabeth Gallegos | Director; Chief Executive Officer | Jun 2023 |
| Gerald Steiner | Director | Jun 2023 |
| Michael Gillespie | Director | Jun 2023 |
| Neal Gutterson | Director | Jun 2023 |
| Glendon Schuster | Director | Oct 2021 |
| Steven Slater | Director | Oct 2021 |
| Wesley Selke | Director | Oct 2021 |